10,803 Results

Interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine evaluating MultiTAA T cell therapy in patients with pancreatic adenocarcinoma.- Marker Therapeutics

 Added 1 day ago

Marker Therapeutics, Inc. announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine , evaluating...

FDA approves Otelza for the treatment of oral ulcers associated with Behçet’s disease.

 Added 1 day ago

Celgene Corporation announced that the FDA has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult...

FDA 510(k) clearance for LifeSPARC system advanced circulatory support (ACS) pump.- LivaNova PLC

 Added 2 days ago

LivaNova PLC announced it has received 510(k) clearance from the FDA for its new Advanced Circulatory Support (ACS) pump and...

Janssen Biotech applied to EMA for extension of the Darzalex marketing authorization for subcutaneous formulation in multiple myeloma indications.

 Added 2 days ago

Genmab A/S announced that its licensing partner, Janssen Biotech, Inc., has submitted an application for the extension of the Darzalex...

Alkermes to expand the proposed NDA for ALKS 3831 to include bipolar 1 disorder as well as schizophrenia .

 Added 2 days ago

Alkermes provided an update on its regulatory strategy for ALKS 3831 (olanzapine/samidorphan), the company's investigational, novel, once-daily, oral atypical antipsychotic...

CE Mark for ProFound AI for 2D mammography software system to analyze 2D mammography scans . ICAD

 Added 2 days ago

ICAD, has secured European CE Mark approval for its ProFound AI for 2D Mammography software system. The product relies on...

AbbVi acquires Mavupharma and with it MAVU 104, a first-in-class, orally active, small molecule inhibitor of ENPP1 an enzyme involved in the regulation of the STING pathway

 Added 3 days ago

AbbVie announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the...

LivaNova launches Bi-Flow to prevent limb ischemia during cardiac surgery.

 Added 3 days ago

LivaNova PLC launched its innovative arterial femoral cannula, Bi-Flow, designed to prevent limb ischemia during cardiac surgery. LivaNova Bi-Flow received...

Seattle Genetics + Astellas submit a BLA to the FDA for accelerated approval for enfortumab vedotin for metastatic urothelial cancer.

 Added 3 days ago

Seattle Genetics, Inc. and Astellas Pharma Inc. announced submission of a Biologics License Application for accelerated approval to the FDA...

FDA accepts NDA to make Procysbi available as oral granules in packets to treat nephropathic cystinosis.- Horizon Therapeutics

 Added 3 days ago

Horizon Therapeutics plc announced that the FDA has accepted Horizon’s New Drug Application (NDA) for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral...

Load more